Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion
Published: 01 April 2021
This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.
Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.
Key Learning Objectives
- Describe how and when to prescribe SGLT2 inhibitors
- Identify patients who are suitable for SGLT2 inhibitors
- Provide appropriate patient education and advice when initiating SGLT2 inhibitors
- Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety
- Dr Jas Gill - GP with Special Interest in Cardiology
- Dr Andrew Frankel - Consultant Nephrologist
- Dr Derek Connolly - Consultant Interventional Cardiologist
- Su Down - Nurse Consultant in Diabetes
More from this programme
Welcome and Introductions
GP with Special Interest in Cardiology
Dr Jas Gill is an award-winning GP in North West London. She is a GP with Special Interest in Cardiology at The Hillingdon Hospital NHS Foundation Trust.
Her previous appointments include Clinical Lead for Diabetes in a London Clinical Commissioning Group through which she has helped shape diabetes care across North West London. She has represented at the Diabetes All Party Parliamentary Group. She has published research in diabetes and is author of multiple medical books.
Dr Gill has helped setup and delivers diabetes workshops to many patients and understands the importance of mindset and patient empowerment in order to enable behaviour change. She values the challenge and rewards of supporting patients throughout their journey.